Comparison Between Natural Sleep Endoscopy and Drug-induced Sleep Endoscopy in Patients With Obstructive Sleep Apnea

Sponsor
ethisch.comite@uza.be (Other)
Overall Status
Recruiting
CT.gov ID
NCT04729478
Collaborator
(none)
40
1
2
21.1
1.9

Study Details

Study Description

Brief Summary

Drug-induced sleep endoscopy (DISE) is the most used technique for identifying the obstruction site associated with obstructive sleep apnea (OSA). This is due to the fact that it allows many patients to be examined in a daytime setting. This procedure uses sedative drugs to mimic natural sleep. However, associations with the site of upper airway (UA) collapse during natural sleep remain unclear.

The aim of this explorative study is to identify UA collapse in patients with OSA using endoscopic techniques as well as flow shape characteristics and sound analyses during natural and drug-induced sleep. Furthermore, we want to optimize the measurement set-up of natural sleep endoscopy (NSE).

Detailed Description

Patients with moderate to severe OSA requiring DISE will be recruited for this prospective study at the outpatient clinic. Patients will undergo a NSE at the sleep lab at night, and a DISE at the operating theatre within three months. Both the NSE and DISE set-up will include gold-standard flow measurements, acoustic analysis and esophageal pressure measurements.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Intervention Model Description:
Blinded, prospective, single-center, comparative cohort study.Blinded, prospective, single-center, comparative cohort study.
Masking:
Single (Outcomes Assessor)
Masking Description:
NSE and DISE will be performed by two separate researchers, blinding the ENT surgeon who performs the NSE or DISE for the outcome of the other procedure. This is a blinded study and the researchers will have no knowledge of the patient's characteristics / demographic variables and their history.
Primary Purpose:
Diagnostic
Official Title:
Comparison Between Natural Sleep Endoscopy and Drug-induced Sleep Endoscopy in Patients With Obstructive Sleep Apnea
Actual Study Start Date :
Mar 30, 2021
Anticipated Primary Completion Date :
Aug 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Natural sleep

Natural sleep endoscopy (NSE) OSA patients will be endoscopically evaluated during natural sleep. During NSE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out.

Device: Natural sleep endoscopy
Endoscopy during natural sleep.
Other Names:
  • NSE
  • Other: Drug-induced sleep

    Drug-induced sleep endoscopy (DISE) OSA patients will be endoscopically evaluated during drug-induced sleep. During DISE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out.

    Device: Drug-induced sleep endoscopy
    An intravenous bolus injection of midazolam 1.5 mg will be used to induce sleep. Maintenance of sedated sleep will be obtained by a target-controlled infusion of propofol (2.0-3.0 µg/mL).
    Other Names:
  • DISE
  • Outcome Measures

    Primary Outcome Measures

    1. Endoscopic Classification System [Immediately, during the procedure]

      Comparison of the frequencies of the site, gradation and pattern of upper airway collapse between natural and drug-induced sleep endoscopy.

    Secondary Outcome Measures

    1. Flow shape analysis [Immediately, during the procedure]

      Several parameters extracted from the flow signal, including negative effort dependence (NED), peak inspiratory flow, etc. measured during both natural and drug-induced sleep endoscopy.

    2. Acoustic analysis [Immediately, during the procedure]

      Acoustic analyses measured during both natural and drug-induced sleep endoscopy

    Other Outcome Measures

    1. Apnea-hypopnea index (AHI) [Immediately, during polysomnography]

      The AHI is an index of sleep apnea severity that encompasses the frequency of apneas (cessations in breathing) and hypopneas (reductions in airflow).

    2. Oxygen desaturation index (ODI) [Immediately, during polysomnography]

      The ODI represents the average number of desaturation episodes (≥3%) per hour sleep.

    3. Oxygen saturation (SaO2) [Immediately, during polysomnography]

      Minimal and mean SaO2 (%)

    4. Apnea index [Immediately, during polysomnography]

      The apnea index is an index of sleep apnea severity that encompasses the frequency of apneas.

    5. Arousal index [Immediately, during polysomnography]

      The arousal index is an indirect indicator of sleep apnea severity that encompasses the number of arousals related to total sleep time.

    6. Arousal threshold [Immediately, during polysomnography]

      The occurrence of arousal from sleep with a rise in ventilatory drive.

    7. Daytime sleepiness measured with the Epworth Sleepiness Scale (ESS) [Immediately, before the procedure]

      The probability of falling asleep in various settings and situations in daily life will be assessed. This questionnaire consists of eight questions which can be scored on a four-point Likert-type scale. The lowest score (zero) suggests that the described incident is absent and the highest score (three) suggests the presence of this event. The summation of the eight items can range from 0 to 24.

    8. Checklist Individual Strength questionnaire (CIS20R) for fatigue [Immediately, before the procedure]

      The checklist individual strength (CIS20R) is a 20-item questionnaire to assess the degree of fatigue. The patient selects the most appropriate score on each statement ranging from 1 (yes, this is true) to 7 (no, this is not true). The total score, calculated as the sum of the questions, may yield to a maximum of 140. The CIS20R measures four dimensions of fatigue: fatigue severity (8 items), concentration problems (5 items), reduced motivation (4 items) and activity (3 items).

    9. Snoring intensity measured with a Visual Analogue Scale (VAS) [Immediately, before the procedure]

      The subjective degree of snoring during sleep will be evaluated by the partner of a subject by using a VAS scoring system ranging from 0 (no snoring) to 10 (extreme snoring causing the bed partner to sleep separately). Heavy snoring is determined as a snoring index ≥7.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Diagnosis of OSA with a baseline AHI ≥ 15 per hour based on full polysomnography

    • Body mass index (BMI) ≤ 35 kg/m²

    • Capability of giving informed consent and willingness to undergo NSE

    Exclusion Criteria:
    • Central sleep apnea (defined as CAHI ≥ 30% of total AHI)

    • Inability to sleep in a supine position due to a medical condition

    • Inability of the patient to understand and/or comply to the study procedures

    • Neuromuscular disorders or craniofacial anomalies affecting the UA

    • Sedative medication use (opioids and muscle relaxants)

    • Active psychiatric disorders (psychotic illness, major depression, anxiety attacks, excessive alcohol or drug use)

    • Severe or decompensated cardiac or respiratory diseases

    • Medical history of known causes of tiredness by day or severe sleep disruption (insomnia, PLMS, narcolepsy)

    • Contra-indications for DISE: i.e. fitness for general anesthesia (ASA>3), allergy to sedative agent(s) and an expected extremely difficult airway

    • Pregnancy or willing to become pregnant

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Antwerp University Hospital Edegem Antwerp Belgium 2650

    Sponsors and Collaborators

    • ethisch.comite@uza.be

    Investigators

    • Principal Investigator: Olivier Vanderveken, MD, PhD, University Hospital, Antwerp

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    ethisch.comite@uza.be, Olivier Vanderveken, Professor and Chair Otorhinolaryngology, University Hospital, Antwerp
    ClinicalTrials.gov Identifier:
    NCT04729478
    Other Study ID Numbers:
    • B3002021000006
    First Posted:
    Jan 28, 2021
    Last Update Posted:
    Jul 26, 2021
    Last Verified:
    Jul 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by ethisch.comite@uza.be, Olivier Vanderveken, Professor and Chair Otorhinolaryngology, University Hospital, Antwerp
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 26, 2021